Immunome, Inc. (IMNM)
| Market Cap | 2.36B +206.7% |
| Revenue (ttm) | 4.01M -63.3% |
| Net Income | -224.59M |
| EPS | -2.34 |
| Shares Out | 113.25M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,309,846 |
| Open | 21.56 |
| Previous Close | 22.02 |
| Day's Range | 20.61 - 21.62 |
| 52-Week Range | 7.62 - 27.65 |
| Beta | 2.11 |
| Analysts | Strong Buy |
| Price Target | 35.23 (+57.18%) |
| Earnings Date | May 12, 2026 |
About IMNM
Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-drug conjugates and other oncology therapeutics in the United States. The company develops clinical asset comprising Varegacestat, a gamma secretase inhibitor that is in Phase 3 clinical trial for the treatment of desmoid tumors; and IM-1021, a receptor tyrosine kinase-like orphan receptor 1 antibody-drug conjugate (ADC), which is in Phase 1 clinical trial. It is also developing preclinical assets, including I... [Read more]
Financial Performance
In 2025, Immunome's revenue was $6.94 million, a decrease of -23.23% compared to the previous year's $9.04 million. Losses were -$212.39 million, -27.50% less than in 2024.
Financial StatementsAnalyst Summary
According to 14 analysts, the average rating for IMNM stock is "Strong Buy." The 12-month stock price target is $35.23, which is an increase of 57.18% from the latest price.
News
Immunome price target lowered to $33 from $37 at Leerink
Leerink analyst Andrew Berens lowered the firm’s price target on Immunome (IMNM) to $33 from $37 and keeps an Outperform rating on the shares.
Immunome reports Q1 EPS (48c), consensus (54c)
“This quarter reflects the progress we are making in building Immunome (IMNM) into a multi-program targeted oncology company,” said Clay B. Siegall, Ph.D., President and Chief Executive Officer of Imm...
Immunome Reports First Quarter 2026 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (the “Company”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, announced toda...
Immunome announces submission of NDA for varegacestat in desmoid tumors
Immunome (IMNM) announced the submission of a New Drug Application to the U.S. Food and Drug Administration for varegacestat, an investigational, oral, once-daily gamma secretase inhibitor, for the tr...
Immunome Announces Submission of New Drug Application to U.S. FDA for Varegacestat for the Treatment of Adults with Desmoid Tumors
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company committed to developing first-in-class and best-in-class targeted cancer therapies, today announced the submissi...
Immunome Announces Oral Presentation of Phase 3 RINGSIDE Data at 2026 ASCO Annual Meeting
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company dedicated to developing first-in-class and best-in-class targeted cancer therapies, today announced...
Immunome (IMNM) Price Forecast: Breakout Points to Higher Highs Ahead
Immunome stock shows renewed strength after a pennant breakout, signaling a potential continuation of its recovery trend with upside momentum building toward prior highs.
Immunome Transcript: Leerink Global Healthcare Conference 2026
Varegacestat, a once-daily gamma secretase inhibitor, showed strong phase III results in desmoid cancer and is on track for FDA submission and potential launch by year-end. The pipeline includes next-gen ADCs, with ROR1 ADC data expected this year, and global commercialization strategies are in place.
Immunome price target lowered to $30 from $32 at Lake Street
Lake Street analyst Chad Messer lowered the firm’s price target on Immunome (IMNM) to $30 from $32 and keeps a Buy rating on the shares. Strategic execution remains on track,…
Immunome price target raised to $36 from $33 at Craig-Hallum
Craig-Hallum analyst Adam Vogel raised the firm’s price target on Immunome (IMNM) to $36 from $33 and keeps a Buy rating on the shares. The firm notes Immunome reported FY25…
Immunome price target lowered to $30 from $33 at Stephens
Stephens analyst Sudan Loganathan lowered the firm’s price target on Immunome (IMNM) to $30 from $33 and keeps an Overweight rating on the shares. The firm updated estimates following the…
Immunome price target raised to $39 from $35 at JPMorgan
JPMorgan raised the firm’s price target on Immunome (IMNM) to $39 from $35 and keeps an Overweight rating on the shares. The firm views the company’s Q4 report as a…
Immunome reports FY25 EPS ($2.43), consensus ($2.21)
As of December 31, 2025, cash and cash equivalents totaled $653.5 million, including net proceeds of $432.4 million from the December 2025 financing. Immunome (IMNM) expects its current cash position…
Immunome Reports Full Year 2025 Financial Results and Provides Business Update
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced financial resu...
Immunome Transcript: TD Cowen 46th Annual Health Care Conference
Varegacestat demonstrated strong phase III results in desmoid tumors, with NDA submission planned for Q2 2026 and manufacturing readiness confirmed. The pipeline includes three new ADCs targeting solid tumors, a promising radiotherapy program, and a focus on expanding market share and long-term patient benefit.
Immunome to Present at Upcoming Investor Conferences
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that members o...
Immunome initiated with a Buy at H.C. Wainwright
H.C. Wainwright initiated coverage of Immunome (IMNM) with a Buy rating and $40 price target The company is building a portfolio of “best-in-class, pipeline-in-a-product oncology assets with meaningfu...
Immunome Transcript: Guggenheim Securities Emerging Outlook: Biotech Summit 2026
The pipeline emphasizes targeted oncology therapies, with a lead gamma secretase inhibitor showing strong phase III results in desmoid tumors and an NDA submission expected soon. The ADC platform is advancing with IM-1021 in phase 1, targeting lymphomas, and a radioligand therapy is set to enter clinical trials.
Immunome to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome Transcript: 44th Annual J.P. Morgan Healthcare Conference
AL102 achieved strong Phase III results in desmoid tumors and is on track for NDA submission in Q2, with potential approval by year-end. The pipeline includes a promising ROR1 ADC, three new solid tumor ADC INDs, and a FAP radioligand, all supported by a strong cash position.
Immunome to Present at 44th Annual J.P. Morgan Healthcare Conference
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced that Immunome ...
Immunome 18.625M share Spot Secondary priced at $21.50
The deal priced below last closing price of $23.48. Leerink, JPMorgan, TD Cowen, Goldman Sachs and Guggenheim are acting as joint book running managers for the offering. Published first on…
Immunome Announces Pricing of Public Offering of Common Stock
BOTHELL, Wash.--(BUSINESS WIRE)--Immunome, Inc. (“Immunome”) (Nasdaq: IMNM), a biotechnology company focused on developing first-in-class and best-in-class targeted cancer therapies, today announced t...